PREMM stands for PREdiction Model for gene Mutations. The PREMM prediction model is rigorously tested, widely recognized, and recommended by several professional societies, including the National Comprehensive Cancer Network, the American College of Gastroenterology, and the U.S. Multi-Society Task Force on Colorectal Cancer.

PREMMplus Model

PREMMplus is a clinical prediction algorithm that identifies individuals that should be considered for hereditary cancer risk assessment using multigene panel testing. PREMMplus evaluates an individual’s personal family history of cancer and related conditions for carrying a germline mutation in one of these cancer susceptibility genes: APC, ATM, BRCA1, BRCA2, BRIP1, CDKN2A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, biallelic MUTYH, PALB2, PMS2, PTEN, RAD51C, RAD51D, and TP53.

The PREMMplus model asks about the following cancers and related conditions:

  • Adrenal gland cancer
  • Bile duct cancer
  • Bladder cancer
  • Brain cancer
  • Breast cancer or Ductal Carcinoma In Situ (DCIS)
  • Cervical
  • Colon (large intestine or large bowel) or Rectal cancer
  • Desmoid tumors (abnormal growth[s] that start in connective tissue, which is tissue that gives strength and flexibility to ligaments and muscles)
  • Endometrial/uterine (or "womb") cancer
  • Kidney (renal cell) cancer
  • Leukemia
  • Liver cancer or hepatocellular carcinoma
  • Lung cancer
  • Lymphoma
  • Melanoma
  • Neuroendocrine or carcinoid tumor
  • Pancreatic cancer
  • Renal pelvis or Ureteral cancer
  • Sarcoma
  • Sebaceous gland skin tumors (a very rare skin tumor that starts in the sebaceous glands, which produce our natural skin oils) or Keratoacanthomas (a fast-growing, dome-shaped skin tumor that usually occurs on sun-exposed areas of the body, especially the head, neck, arms, legs, and back of the hands)
  • Small bowel (or small intestine) cancer (this can include cancers of the ileum, jejunum and duodenum)
  • Stomach cancer
  • Ovarian ("cancer of the eggs"), Fallopian tube, or Primary peritoneal cancer
  • Prostate cancer
  • Colorectal polyps (personal history)

The PREMMplus model was introduced in 2022 and identifies individuals that should be considered for hereditary cancer risk assessment using multigene panel testing. Details of model development are available in this publication:

Yurgelun MB, Uno H, Furniss CS, Ukaegbu C, Horiguchi M, Yussuf A, LaDuca H, Chittenden A, Garber JE, Syngal S.
Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment
Journal of Clinical Oncology. 2022 Dec 10; 40 (35):4083-4094.